4-AcO-DET Stats & Data

4-AcO-DET was first synthesized in 1958 by Albert Hofmann at the Sandoz laboratories in Switzerland. Despite this early synthesis, the compound remained largely unexplored for decades and has accumulated very little documented history of human usage. In the contemporary era, 4-AcO-DET has found limited use as both a recreational designer drug and an entheogenic compound, with most users acquiring it through online research chemical vendors. It remains relatively rare compared to more widely documented psychedelics in the tryptamine class.

The toxicity and long-term health effects of recreational 4-AcO-DET has not been studied in any scientific context and the exact toxic dose is unknown. This is because 4-AcO-DET is a research chemical with a very limited history of human usage. However, it is assumed to have a similar toxicity profile as psilocybin due to their structural similarity. Anecdotal reports from those who have tried 4-AcO-DET suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Effects aggregated from 30 experience reports (30 single-substance Erowid)

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Also reported in combinations. In the 20 4-AcO-DET reports where another drug was taken too, 0 (0.0%) mention hospital, emergency services or an overdose, 0 (0.0%) a seizure and 1 (5.0%) psychosis. In the 30 single-substance reports: 0.0%, 0.0% and 0.0%. These are not in the figures above: they cannot be put down to 4-AcO-DET alone, and a mention is not always something that happened to the writer.

Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

From 66 of 75 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Most co-occurring substances, as a share of all 50 reports filed under 4-AcO-DET; whiskers are 95% intervals

Most common forms and preparations, as a share of the 36 reports that give one; whiskers are 95% intervals

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

Redosing behavior across 39 reports